We are live on ! Find out more
MIRM icon

Mirum Pharmaceuticals

272 hedge funds and large institutions have $4.2B invested in Mirum Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 74 funds opening new positions, 91 increasing their positions, 77 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

429% more first-time investments, than exits

New positions opened: 74 | Existing positions closed: 14

49% more capital invested

Capital invested by funds: $2.82B → $4.2B (+$1.38B)

27% more funds holding

Funds holding: 214272 (+58)

18% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 77

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

2.32% more ownership

Funds ownership: 111.83%114.15% (+2.3%)

8% less call options, than puts

Call options by funds: $7.16M | Put options by funds: $7.75M

Holders
272
Holders Change
+58
Holders Change %
+27.1%
% of All Funds
3.57%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.13%
New
74
Increased
91
Reduced
77
Closed
14
Calls
$7.16M
Puts
$7.75M
Net Calls
-$587K
Net Calls Change
+$2.92M
Name Holding Trade Value Shares
Change
Change in
Stake
Russell Investments Group
51
Russell Investments Group
United Kingdom
$20.4M +$1.97M +31,030 +13%
Two Sigma Advisers
52
Two Sigma Advisers
New York
$20.3M +$6.67M +105,000 +61%
UBS Group
53
UBS Group
Switzerland
$20.2M +$5.94M +93,386 +51%
AIM
54
AXA Investment Managers
France
$18.7M +$16.3M +255,688 New
Jane Street
55
Jane Street
New York
$18.7M +$14.8M +233,047 +1,087%
Raymond James Financial
56
Raymond James Financial
Florida
$18.5M -$787K -12,385 -5%
EAM
57
Erste Asset Management
Austria
$18.2M -$636K -10,000 -4%
New York State Common Retirement Fund
58
New York State Common Retirement Fund
New York
$17.8M -$411K -6,470 -3%
EMFAT
59
Emerald Mutual Fund Advisers Trust
Pennsylvania
$16.1M +$95.1K +1,496 +0.7%
NIP
60
Nicholas Investment Partners
California
$15.9M +$2.07M +32,585 +18%
Ameriprise
61
Ameriprise
Minnesota
$14.9M -$2.52M -39,692 -16%
AG
62
Algert Global
California
$14M +$1.99M +31,250 +20%
Deutsche Bank
63
Deutsche Bank
Germany
$13.5M +$1.82M +28,703 +18%
Legal & General Group
64
Legal & General Group
United Kingdom
$12.3M +$7.9M +124,220 +289%
RHJA
65
Rice Hall James & Associates
California
$12.1M -$4.27M -67,247 -29%
JF
66
Jump Financial
Illinois
$11.9M +$853K +13,411 +9%
NFT
67
Nan Fung Trinity
Hong Kong
$11.5M +$604K +9,500 +6%
SCM
68
Soleus Capital Management
Connecticut
$10.9M -$9.54M -150,000 -50%
Citigroup
69
Citigroup
New York
$10.8M +$4.87M +76,545 +108%
PP
70
PDT Partners
New York
$10.7M
First Trust Advisors
71
First Trust Advisors
Illinois
$10.6M +$919K +14,454 +11%
CSS
72
Cubist Systematic Strategies
Connecticut
$10.6M -$48.7K -766 -0.5%
Ensign Peak Advisors
73
Ensign Peak Advisors
Utah
$9.82M
Squarepoint
74
Squarepoint
New York
$9.38M +$6.97M +109,626 +600%
HP
75
Highlander Partners
Texas
$9.02M

MIRM Hedge Fund Activity: Q3 2025 in Review

272 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q3 2025, worth a combined $4.2B — up 49% from $2.82B a quarter earlier.

Buyers outnumbered sellers: 74 funds opened new MIRM positions and 14 closed out — a net gain of 60 holders — while 91 added to existing stakes and 77 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $42.7M. The largest seller was BVF Inc, cutting an estimated $80.5M.

  • 272 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q3 2025, up from 214 in Q2 2025.
  • Funds reported $4.2B of Mirum Pharmaceuticals stock for Q3 2025, up 49% quarter-over-quarter.
  • 74 funds opened new Mirum Pharmaceuticals positions in Q3 2025 and 14 closed out, a net change of +60 holders.
  • The largest Mirum Pharmaceuticals buyer in Q3 2025 was Wellington Management Group, an estimated $42.7M added.
  • The largest Mirum Pharmaceuticals seller in Q3 2025 was BVF Inc, an estimated $80.5M sold.

Based on aggregated 13F filings for Q3 2025.